CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 35 filers reported holding CRISPR THERAPEUTICS AG in Q1 2017. The put-call ratio across all filers is - and the average weighting 1.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,224,928 | -18.0% | 203,238 | +1.4% | 0.00% | 0.0% |
| Q2 2023 | $11,252,786 | +20.4% | 200,442 | -3.0% | 0.00% | 0.0% |
| Q1 2023 | $9,344,292 | +68.2% | 206,595 | +51.2% | 0.00% | +50.0% |
| Q4 2022 | $5,555,351 | -39.1% | 136,663 | -2.1% | 0.00% | -33.3% |
| Q3 2022 | $9,127,000 | +8.4% | 139,652 | +0.8% | 0.00% | 0.0% |
| Q2 2022 | $8,417,000 | -31.5% | 138,507 | -29.3% | 0.00% | 0.0% |
| Q1 2022 | $12,296,000 | -15.6% | 195,887 | +1.9% | 0.00% | -25.0% |
| Q4 2021 | $14,564,000 | -71.9% | 192,189 | -58.5% | 0.00% | -63.6% |
| Q3 2021 | $51,805,000 | -31.4% | 462,840 | -0.8% | 0.01% | -35.3% |
| Q2 2021 | $75,527,000 | +63.2% | 466,532 | +22.8% | 0.02% | +70.0% |
| Q1 2021 | $46,283,000 | -34.9% | 379,842 | -18.2% | 0.01% | -41.2% |
| Q4 2020 | $71,123,000 | +51.7% | 464,518 | -17.1% | 0.02% | +30.8% |
| Q3 2020 | $46,895,000 | +17.6% | 560,660 | +3.4% | 0.01% | +8.3% |
| Q2 2020 | $39,860,000 | +87.4% | 542,402 | +8.2% | 0.01% | +71.4% |
| Q1 2020 | $21,270,000 | -14.3% | 501,519 | +23.1% | 0.01% | 0.0% |
| Q4 2019 | $24,811,000 | +16.2% | 407,382 | -21.8% | 0.01% | +16.7% |
| Q3 2019 | $21,351,000 | -24.9% | 520,905 | -13.7% | 0.01% | -25.0% |
| Q2 2019 | $28,443,000 | +63.4% | 603,905 | +23.9% | 0.01% | +60.0% |
| Q1 2019 | $17,408,000 | +28.4% | 487,365 | +2.7% | 0.01% | 0.0% |
| Q4 2018 | $13,558,000 | -28.7% | 474,579 | +10.7% | 0.01% | 0.0% |
| Q3 2018 | $19,021,000 | -11.0% | 428,895 | +17.9% | 0.01% | -16.7% |
| Q2 2018 | $21,368,000 | +1.3% | 363,657 | -21.2% | 0.01% | 0.0% |
| Q1 2018 | $21,089,000 | +4076.0% | 461,377 | +2044.2% | 0.01% | – |
| Q4 2017 | $505,000 | +54.0% | 21,517 | +17.2% | 0.00% | – |
| Q3 2017 | $328,000 | +156.2% | 18,352 | +129.8% | 0.00% | – |
| Q2 2017 | $128,000 | +312.9% | 7,987 | +459.7% | 0.00% | – |
| Q1 2017 | $31,000 | +55.0% | 1,427 | +45.6% | 0.00% | – |
| Q4 2016 | $20,000 | – | 980 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |